HomeCVM • NYSEAMERICAN
CEL-SCI Corp
$1.91
Mar 28, 4:16:33 PM GMT-4 · USD · NYSEAMERICAN · Disclaimer
StockUS listed securityUS headquartered
Previous close
$1.89
Day range
$1.81 - $1.91
Year range
$1.04 - $3.23
Market cap
103.10M USD
Avg Volume
379.14K
P/E ratio
-
Dividend yield
-
Market news
Financials
Income Statement
Revenue
Net income
(USD)Dec 2023Y/Y change
Revenue
Operating expense
2.13M-5.52%
Net income
-6.71M16.39%
Net profit margin
Earnings per share
EBITDA
-5.48M17.72%
Effective tax rate
Total assets
Total liabilities
(USD)Dec 2023Y/Y change
Cash and short-term investments
3.26M-81.92%
Total assets
28.71M-35.57%
Total liabilities
16.06M-10.61%
Total equity
12.65M
Shares outstanding
50.10M
Price to book
7.56
Return on assets
-54.74%
Return on capital
-61.73%
Net change in cash
(USD)Dec 2023Y/Y change
Net income
-6.71M16.39%
Cash from operations
-4.89M-4.74%
Cash from investing
-64.86K-21.05%
Cash from financing
4.05M6,089.41%
Net change in cash
-904.30K80.57%
Free cash flow
-2.50M-50.83%
About
Cel-Sci Corporation, is a biotechnology company that tests drugs for the treatment of cancer, autoimmune and infectious diseases through the research and development of immunotherapy products. Cel-Sci's main product is the drug Multikine, an immunotherapeutic agent designed to fight cancer by stimulating the body's immune system. Multikine is currently in Phase III of Clinical Trials with the Food and Drug Administration. Multikine has also been referred to as Leukocyte Interleukin Injection. Multikine was in Phase II testing of patients with head and neck cancer in the early 2000s, in which it demonstrated tumor-reducing ability. In January 2007, the US cleared the Phase 3 trial and Multikine was designated as an orphan drug by the FDA for neoadjuvant therapy of patients with squamous cell carcinoma of the head and neck. A total of 928 patients were enrolled in the head and neck cancer drug trial at that time. Subsequently, in June of 2021, the company announced that the study missed its primary endpoint. Wikipedia
Founded
Mar 1983
Employees
43
Discover more
You may be interested in
This list is generated from recent searches, followed securities, and other activity. Learn more

All data and information is provided “as is” for personal informational purposes only, and is not intended to be financial advice nor is it for trading purposes or investment, tax, legal, accounting or other advice. Google is not an investment adviser nor is it a financial adviser and expresses no view, recommendation or opinion with respect to any of the companies included in this list or any securities issued by those companies. Please consult your broker or financial representative to verify pricing before executing any trades. Learn more
People also search for
Search
Clear search
Close search
Google apps
Main menu